SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
Long-Term Debt
SCI Pharmtech Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Long-Term Debt
NT$584.4m
|
CAGR 3-Years
908%
|
CAGR 5-Years
245%
|
CAGR 10-Years
0%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Long-Term Debt
NT$437.6m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Long-Term Debt
NT$2.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
2%
|
CAGR 10-Years
9%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Long-Term Debt
NT$620.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Long-Term Debt
NT$8.6B
|
CAGR 3-Years
22%
|
CAGR 5-Years
17%
|
CAGR 10-Years
9%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Long-Term Debt
NT$367.6m
|
CAGR 3-Years
8%
|
CAGR 5-Years
21%
|
CAGR 10-Years
7%
|
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Long-Term Debt?
Long-Term Debt
584.4m
TWD
Based on the financial report for Dec 31, 2024, SCI Pharmtech Inc's Long-Term Debt amounts to 584.4m TWD.
What is SCI Pharmtech Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
0%
Over the last year, the Long-Term Debt growth was -31%. The average annual Long-Term Debt growth rates for SCI Pharmtech Inc have been 908% over the past three years , 245% over the past five years .
You don't have any saved screeners yet